Stock movement looks familiar.
Will the pattern hold?
Also, Botox rival, Revance Therapeutics, got approved. Longer lasting than Botox. Remains to be seen if it can eat into ABBV's market share.
Also, Botox rival, Revance Therapeutics, got approved. Longer lasting than Botox. Remains to be seen if it can eat into ABBV's market share.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。